Products for Research Use Only

Topiroxostat-d4

CAT: 0804-HY-14874S-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14874S-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%) . Topiroxostat has the potential for hyperuricemia treatment[1][2].
CAS Number
2732868-49-2
Product Name Alternative
FYX-051-d4
UNSPSC
12352005
Target
Cytochrome P450; Isotope-Labeled Compounds; Xanthine Oxidase
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease; Others
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
N#CC1=NC=CC(C2=NN=C(C3=C([2H])C([2H])=NC([2H])=C3[2H])N2)=C1
Molecular Formula
C13H4D4N6
Molecular Weight
252.27
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336 (1) :95-103.|[3]Sato T, et al. Discovery of 3- (2-cyano-4-pyridyl) -5- (4-pyridyl) -1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19 (21) :6225-9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported